3D Systems - Die nächste Apple? - Älteste Beiträge zuerst (Seite 76) | Diskussion im Forum
eröffnet am 05.11.12 20:43:11 von
neuester Beitrag 21.10.23 18:29:55 von
neuester Beitrag 21.10.23 18:29:55 von
Beiträge: 1.446
ID: 1.177.635
ID: 1.177.635
Aufrufe heute: 4
Gesamt: 237.228
Gesamt: 237.228
Aktive User: 0
ISIN: US88554D2053 · WKN: 888346
3,2600
EUR
-0,31 %
-0,0100 EUR
Letzter Kurs 22:28:11 Lang & Schwarz
Neuigkeiten
15.04.24 · globenewswire  |
22.03.24 · globenewswire |
12.03.24 · globenewswire |
05.03.24 · globenewswire |
28.02.24 · globenewswire |
Werte aus der Branche Hardware
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5150 | +37,70 | |
| 0,7000 | +15,70 | |
| 2,7200 | +12,40 | |
| 2,0400 | +9,68 | |
| 8,8250 | +6,97 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 685,20 | -4,83 | |
| 161,15 | -6,11 | |
| 1,8420 | -9,68 | |
| 1,4000 | -13,04 | |
| 6,2000 | -25,66 |
Feedback
Dickes Brett vor dem Kopf, wenn ich schon so was wieder lese...es kommt mir vor als hat Aktiendre.. staendig ein dickes Brett vor dem Kopf (nmpM).
3D Systems-Aktie: Hohes Maß an Short-Positionen könnte zur Eindeckung von Leerverkaufspositionen führen! - Aktienanalyse
In einer aktuellen Aktienanalyse bekräftigt Analyst Amit Daryanani von RBC Capital Markets bezüglich der Aktien von 3D Systems Corporation (ISIN: US88554D2053, WKN: 888346, Ticker-Symbol: SYV, NYSE-Symbol: DDD) die Erwartung einer überdurchschnittlichen Kursentwicklung.
Nach Presseberichten im Hinblick auf das Absagen der Teilnahme an einer Konferenz habe man die Möglichkeit gehabt mit dem Management zu sprechen. Nach Angaben der Analysten von RBC Capital Markets hat es den Anschein, als ob 3D Systems Corp. die Teilnahme vorläufig geplant habe. Auf Grund von Konflikten im Management sei aber nun beschlossen worden, die Teilnahme abzusagen.
Die Bewegungen beim Aktienkurs hätten überrascht. Analyst Amit Daryanani glaubt, dass sich die Fundamentaldaten im zweiten Halbjahr wesentlich verbessern würden. Dies sollte der Aktie Unterstützung geben. Angesichts des hohen Short-Anteils bei den 3D Systems-Aktien könnte es zur Eindeckung von Leerverkaufspositionen kommen.
Die Aktienanalysten von RBC Capital Markets bleiben in ihrer 3D Systems-Aktienanalyse beim Votum "outperform" sowie dem Kursziel von 64,00 USD.
http://www.aktiencheck.de/kolumnen/Artikel-3D_Systems_Aktie_…
In einer aktuellen Aktienanalyse bekräftigt Analyst Amit Daryanani von RBC Capital Markets bezüglich der Aktien von 3D Systems Corporation (ISIN: US88554D2053, WKN: 888346, Ticker-Symbol: SYV, NYSE-Symbol: DDD) die Erwartung einer überdurchschnittlichen Kursentwicklung.
Nach Presseberichten im Hinblick auf das Absagen der Teilnahme an einer Konferenz habe man die Möglichkeit gehabt mit dem Management zu sprechen. Nach Angaben der Analysten von RBC Capital Markets hat es den Anschein, als ob 3D Systems Corp. die Teilnahme vorläufig geplant habe. Auf Grund von Konflikten im Management sei aber nun beschlossen worden, die Teilnahme abzusagen.
Die Bewegungen beim Aktienkurs hätten überrascht. Analyst Amit Daryanani glaubt, dass sich die Fundamentaldaten im zweiten Halbjahr wesentlich verbessern würden. Dies sollte der Aktie Unterstützung geben. Angesichts des hohen Short-Anteils bei den 3D Systems-Aktien könnte es zur Eindeckung von Leerverkaufspositionen kommen.
Die Aktienanalysten von RBC Capital Markets bleiben in ihrer 3D Systems-Aktienanalyse beim Votum "outperform" sowie dem Kursziel von 64,00 USD.
http://www.aktiencheck.de/kolumnen/Artikel-3D_Systems_Aktie_…
http://www.aktiencheck.de/exklusiv/Artikel-3D_Systems_Aktie_…
der erfolg von 3D ist für mich nur eine zeitfrage.
bonne fin de journée
der erfolg von 3D ist für mich nur eine zeitfrage.
bonne fin de journée
Trading Spotlight
3D Systems Announces Purchase of Simbionix for $120M in Cash 
http://www.benzinga.com/news/14/07/4743459/update-3d-systems…
3D Systems (NYSE: DDD) announced today that it entered into a definitive agreement to acquire Simbionix for $120 million in cash, subject to customary closing adjustments. Simbionix is the global leader in 3D virtual reality surgical simulation and training with 60+ interventional procedures across 8 specialties through 16 simulation platforms — a complementary building block that expands 3DS's breadth and reach within the open-ended 3D healthcare field. The transaction is expected to be completed within the next 30 days, subject to customary closing conditions. Upon closing, 3DS expects this acquisition to be immediately accretive to its cash generation and to its non-GAAP earnings per share.
"Simbionix is a perfect match for our healthcare business and its powerful technology, products, channels and domain expertise expands our 3D healthcare capabilities from the training room to the operating room, and extends our first mover advantage in this fast growing vertical," said Avi Reichental, President and Chief Executive Officer, 3DS.
Headquartered in Cleveland, Ohio with a research and development center in Israel, Simbionix pioneered patient-specific simulation with FDA-cleared solutions that are changing the way preparation for individual surgeries are carried out. Its proprietary simulation and training products are revolutionizing the way physicians practice and master surgical procedures with improved learning that can favorably impact patient outcomes.
"3D Systems is the recognized 3D healthcare leader and they have an exceptional track record of commercially deploying innovative virtual surgery and medical device products and services," said Gary Zamler, Simbionix Corporation CEO. "We couldn't be more excited to join this fine organization and look forward to accelerate our growth by enhancing the entire 3D digital thread for the benefit of our customers worldwide."
The recent acquisition of industry leader Medical Modeling brought to 3DS world-class clinical capabilities in Virtual Surgical Planning (VSP®), guiding and instrumenting of complex personalized surgical procedures, production at scale of 3D printed implants, and delivery of a wide variety of 3D printed patient-specific medical devices.
In addition to synergistic technology and products, Simbionix brings to 3DS global sales channels and deep clinical relationships to accelerate the adoption of best medical practices, to advance clinical performance, and to optimize procedural outcomes. The company's products can be found in simulation centers, hospitals, colleges and other educational facilities in over 60 countries.
The company plans to operate Simbionix under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager, Simbionix Products for 3DS and immediately pursue synergistic integration opportunities leveraging the combined resources and expertise to advance 3DS' healthcare portfolio further and faster.
Management plans to include a more detailed discussion of this transaction as part of its previously scheduled conference call and simultaneous webcast to review its financial results for the second quarter and first six months of 2014 at 9:00am ET on July 31, 2014. The company also plans to file its second quarter earnings release at 8:30 a.m. ET and its Form 10-Q before the NYSE market opens.
Date: Thursday, July 31, 2014
Time: 9:00 a.m. Eastern Time
Read more: http://www.benzinga.com/news/14/07/4743459/update-3d-systems…#ixzz3906xrb2S
http://www.benzinga.com/news/14/07/4743459/update-3d-systems…
3D Systems (NYSE: DDD) announced today that it entered into a definitive agreement to acquire Simbionix for $120 million in cash, subject to customary closing adjustments. Simbionix is the global leader in 3D virtual reality surgical simulation and training with 60+ interventional procedures across 8 specialties through 16 simulation platforms — a complementary building block that expands 3DS's breadth and reach within the open-ended 3D healthcare field. The transaction is expected to be completed within the next 30 days, subject to customary closing conditions. Upon closing, 3DS expects this acquisition to be immediately accretive to its cash generation and to its non-GAAP earnings per share.
"Simbionix is a perfect match for our healthcare business and its powerful technology, products, channels and domain expertise expands our 3D healthcare capabilities from the training room to the operating room, and extends our first mover advantage in this fast growing vertical," said Avi Reichental, President and Chief Executive Officer, 3DS.
Headquartered in Cleveland, Ohio with a research and development center in Israel, Simbionix pioneered patient-specific simulation with FDA-cleared solutions that are changing the way preparation for individual surgeries are carried out. Its proprietary simulation and training products are revolutionizing the way physicians practice and master surgical procedures with improved learning that can favorably impact patient outcomes.
"3D Systems is the recognized 3D healthcare leader and they have an exceptional track record of commercially deploying innovative virtual surgery and medical device products and services," said Gary Zamler, Simbionix Corporation CEO. "We couldn't be more excited to join this fine organization and look forward to accelerate our growth by enhancing the entire 3D digital thread for the benefit of our customers worldwide."
The recent acquisition of industry leader Medical Modeling brought to 3DS world-class clinical capabilities in Virtual Surgical Planning (VSP®), guiding and instrumenting of complex personalized surgical procedures, production at scale of 3D printed implants, and delivery of a wide variety of 3D printed patient-specific medical devices.
In addition to synergistic technology and products, Simbionix brings to 3DS global sales channels and deep clinical relationships to accelerate the adoption of best medical practices, to advance clinical performance, and to optimize procedural outcomes. The company's products can be found in simulation centers, hospitals, colleges and other educational facilities in over 60 countries.
The company plans to operate Simbionix under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager, Simbionix Products for 3DS and immediately pursue synergistic integration opportunities leveraging the combined resources and expertise to advance 3DS' healthcare portfolio further and faster.
Management plans to include a more detailed discussion of this transaction as part of its previously scheduled conference call and simultaneous webcast to review its financial results for the second quarter and first six months of 2014 at 9:00am ET on July 31, 2014. The company also plans to file its second quarter earnings release at 8:30 a.m. ET and its Form 10-Q before the NYSE market opens.
Date: Thursday, July 31, 2014
Time: 9:00 a.m. Eastern Time
Read more: http://www.benzinga.com/news/14/07/4743459/update-3d-systems…#ixzz3906xrb2S
Wollen wir mal hoffen, dass dies morgen positiv aufgenommen wird.
sieht nicht so aus!
Heute über 12% Kursrückgang- Warum?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,05 | |
| -4,71 | |
| -3,62 | |
| +1,68 | |
| +3,03 | |
| -7,47 | |
| +0,01 | |
| +2,88 | |
| +0,30 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 212 | ||
| 207 | ||
| 188 | ||
| 68 | ||
| 32 | ||
| 29 | ||
| 28 | ||
| 28 | ||
| 26 | ||
| 25 |
